汇宇制药(688553)
 
 
  日线
顶尖财经网欢迎您!
  K线
 
 最新动态
  投资评级

研究机构 评级日期 最新评级 上次评级
暂无数据
  盈利预测
据汇宇制药三季报分析:

  盈利能力有所削弱,总资产收益能力大幅下降

  成长能力维持稳定,公司规模加速扩张

  偿债能力有所削弱,财务杠杆风险加大

  运营能力维持稳定,资金占用情况严重恶化

  现金流能力有所削弱,公司的资金利用效率遭到削弱

  财务数据
    截至第三季度实现净利润0.89亿元,每股收益0.21元。

    截至第三季度最新股东权益370848.24万元,未分配利润71932.78万元。

    截至第三季度最新总资产454199.94万元,负债83351.70万元。

利润表
报告期2023-09-302023-06-302023-03-312022-12-31
营业总收入659,136,821.28450,574,708.72237,720,069.61,493,267,942.75
营业总成本636,486,700.96429,327,974.78223,832,381.91,304,311,711.09
营业利润63,359,572.6152,198,263.3227,477,149.03235,448,350.37
利润总额73,198,525.3759,363,781.9333,484,786.35238,391,474.13
净利润88,745,298.0668,584,891.8738,395,308.1248,990,617.28
其他综合收益171,648.3223,987.6261,461.87-223,364.66
综合收益总额88,916,946.3668,808,879.4938,456,769.97248,855,089.71
资产负债表
报告期2023-09-302023-06-302023-03-312022-12-31
流动资产合计2,901,798,334.452,782,834,260.462,859,140,587.162,873,206,406.43
非流动资产合计1,640,201,041.841,586,757,263.981,506,652,054.731,403,303,395.46
资产总计4,541,999,376.294,369,591,524.444,365,792,641.894,276,509,801.89
流动负债合计799,581,177.83652,173,707.55577,501,189.25526,393,572.77
非流动负债合计33,935,788.0829,043,473.3831,760,359.6632,041,906.11
负债合计833,516,965.91681,217,180.93609,261,548.91558,435,478.88
归属于母公司股东权益合计3,708,317,238.693,688,131,771.973,756,531,092.983,718,074,323.01
股东权益合计3,708,482,410.383,688,374,343.513,756,531,092.983,718,074,323.01
负债和股东权益合计4,541,999,376.294,369,591,524.444,365,792,641.894,276,509,801.89
现金流量表
报告期2023-09-302023-06-302023-03-312022-12-31
经营活动现金流入小计791,754,640.92577,667,706.82237,486,856.731,646,582,854.36
经营活动现金流出小计771,202,926.33509,111,503.01293,260,438.911,452,522,504.92
经营活动产生的现金流量净额20,551,714.5968,556,203.81-55,773,582.18194,060,349.44
投资活动现金流入小计3,057,830,559.012,456,033,987.221,468,048,166.065,258,578,849.99
投资活动现金流出小计2,746,212,170.952,149,306,487.481,481,456,442.275,439,613,179.06
投资活动产生的现金流量净额311,618,388.06306,727,499.74-13,408,276.21-181,034,329.07
筹资活动现金流入小计382,500,000115,500,000114,500,00057,447,150
筹资活动现金流出小计146,054,452.76145,643,583.32319,465.97157,437,201.55
筹资活动产生的现金流量净额236,445,547.24-30,143,583.32114,180,534.03-99,990,051.55
汇率变动对现金及现金等价物的影响----160,952.94
现金及现金等价物净增加额568,615,649.89345,140,120.2344,998,675.64-87,124,984.12
期末现金及现金等价物余额1,774,460,423.451,550,984,893.791,250,847,149.191,205,844,773.56
  主营收入+营业利润
 
  净利润+每股收益
  股东权益+未分配利润
 
  总资产+负债
  投资要点

    截至第三季度实现净利润0.89亿元,每股收益0.21元。

    截至第三季度最新股东权益370848.24万元,未分配利润71932.78万元。

    截至第三季度最新总资产454199.94万元,负债83351.70万元。

利润表
报告期2023-09-302023-06-302023-03-312022-12-31
营业总收入659,136,821.28450,574,708.72237,720,069.61,493,267,942.75
营业总成本636,486,700.96429,327,974.78223,832,381.91,304,311,711.09
营业利润63,359,572.6152,198,263.3227,477,149.03235,448,350.37
利润总额73,198,525.3759,363,781.9333,484,786.35238,391,474.13
净利润88,745,298.0668,584,891.8738,395,308.1248,990,617.28
其他综合收益171,648.3223,987.6261,461.87-223,364.66
综合收益总额88,916,946.3668,808,879.4938,456,769.97248,855,089.71
资产负债表
报告期2023-09-302023-06-302023-03-312022-12-31
流动资产合计2,901,798,334.452,782,834,260.462,859,140,587.162,873,206,406.43
非流动资产合计1,640,201,041.841,586,757,263.981,506,652,054.731,403,303,395.46
资产总计4,541,999,376.294,369,591,524.444,365,792,641.894,276,509,801.89
流动负债合计799,581,177.83652,173,707.55577,501,189.25526,393,572.77
非流动负债合计33,935,788.0829,043,473.3831,760,359.6632,041,906.11
负债合计833,516,965.91681,217,180.93609,261,548.91558,435,478.88
归属于母公司股东权益合计3,708,317,238.693,688,131,771.973,756,531,092.983,718,074,323.01
股东权益合计3,708,482,410.383,688,374,343.513,756,531,092.983,718,074,323.01
负债和股东权益合计4,541,999,376.294,369,591,524.444,365,792,641.894,276,509,801.89
现金流量表
报告期2023-09-302023-06-302023-03-312022-12-31
经营活动现金流入小计791,754,640.92577,667,706.82237,486,856.731,646,582,854.36
经营活动现金流出小计771,202,926.33509,111,503.01293,260,438.911,452,522,504.92
经营活动产生的现金流量净额20,551,714.5968,556,203.81-55,773,582.18194,060,349.44
投资活动现金流入小计3,057,830,559.012,456,033,987.221,468,048,166.065,258,578,849.99
投资活动现金流出小计2,746,212,170.952,149,306,487.481,481,456,442.275,439,613,179.06
投资活动产生的现金流量净额311,618,388.06306,727,499.74-13,408,276.21-181,034,329.07
筹资活动现金流入小计382,500,000115,500,000114,500,00057,447,150
筹资活动现金流出小计146,054,452.76145,643,583.32319,465.97157,437,201.55
筹资活动产生的现金流量净额236,445,547.24-30,143,583.32114,180,534.03-99,990,051.55
汇率变动对现金及现金等价物的影响----160,952.94
现金及现金等价物净增加额568,615,649.89345,140,120.2344,998,675.64-87,124,984.12
期末现金及现金等价物余额1,774,460,423.451,550,984,893.791,250,847,149.191,205,844,773.56
  十大流通股东
十大流通股东 报告期:2023-09-30
股东名称 持股数量(万股) 占总股本比例(%) 上期持股变化(万股)
黄乾益3069.6910.61-972.42
杨波2119.007.330.00
王晓鹏1703.765.89-60.64
曹永明1694.405.86847.20
上海爽飒企业管理咨询事务所(有限合伙)1269.564.390.00
谭娟1221.504.220.00
吴水花610.092.110.00
上海阿杏投资管理有限公司-阿杏东方私募证券投资基金542.531.880.00
孔益明481.181.660.00
郎志江481.181.66481.18
  主力控盘
  公司简介
汇宇制药 所属地域: 四川省 涉及概念: 重组蛋白,CRO概念,创新药,仿制药一致性评价,融资融券
主营业务: 许可项目:药品生产;药品进出口(依法须经批准的项目,经相关部门批准方可开展经营活动,具体经营项目以相关部门批准文件或许可证件为准)一般项目:技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广;食品销售(仅销售预包装食品)(除依法须经批准的项目外,凭营业执照依法自主开展经营活动)。
上市日期: 2021-10-26 每股净资产: 8.75元 每股收益: 0.21元 净利润: 0.89亿元 净利润增长率: -62.21%
营业收入: 6.59亿元 每股现金流: 0.05元 每股公积金: 5.84元 每股未分配利润: 1.70元 总股本: 4.24亿 流通股: 2.91亿
以上信息为合作方、加盟公司及会员收集,本站不拥有版权,版权归原作者所有,所载文章、数据仅供参考,据此操作,风险自负。

中 华 顶 尖 财 经 -- 中 华 顶 尖 网 络 信 息 服 务 中 心